Tag: myelodysplastic syndrome (MDS) drugs market trends

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Forecast for the Myelodysplastic Syndrome (MDS) Drugs Market from 2024 to 2025?#_x000D_

The market for drugs treating myelodysplastic syndrome (MDS) has seen robust growth in recent years. Its size is projected to expand from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.5%. The considerable growth during historical periods can be credited to an aging population, progress in targeted treatments, clinical studies, and heightened awareness._x000D_

_x000D_

#What Is the Projected Market Size of the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_

In the forthcoming years, the market size of drugs for myelodysplastic syndrome (MDS) is likely to witness considerable expansion. It is predicted to reach a value of $5.12 billion by 2029, growing at an annual compound rate (CAGR) of 8.2%. This projected growth can be associated with factors such as genomic research, immunotherapies, healthcare expansion worldwide, and biomarker discovery. Notable tendencies for the forecasted period involve personalized medicine, combination therapies, symptom management, as well as data sharing and cooperation._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp_x000D_

_x000D_

#Who are the Major Competitors in the Myelodysplastic Syndrome (MDS) Drugs Market Outlook?#_x000D_

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc._x000D_

_x000D_

#What Is Fueling Growth in the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_

The growth of the myelodysplastic syndrome (MDS) drug market is anticipated to be driven by the increased prevalence of cancer treatments, such as chemotherapy and radiation. These types of treatments, which use medication to eliminate cancer cells and employ high radiation doses to eradicate cancer cells and diminish tumours, have the potential to harm the bone marrow’s stem cells. These cells are responsible for the production of new blood cells and their impairment interrupts the natural equilibrium of cell production, leading to the development of MDS. Medications for myelodysplastic syndrome (MDS) have been found to be beneficial in managing and treating the disorder, which is associated with irregular blood cell production in the bone marrow. Upon analysis by the European Society of Radiation Oncology (ESTRO), the anticipated cancer distribution in 2025 will lead to a 16% increase in radiotherapy treatment courses. This growth in cancer treatments, including chemotherapy and radiation, is therefore projected to be a driving force for the MDS drugs market. The myelodysplastic syndrome (MDS) drug treatment market is projected to be further boosted by the rising incidences of myeloid leukemia. Myeloid leukemia, a cancer type that originates in the bone marrow and affects the cell production of various types of blood cells, is seen as a growing major concern. MDS drugs target the root cause of leukemia to lessen the chances of complications, such as low blood cell counts, and reduce the need for intensive treatments such as chemotherapy and transplants while simultaneously improving survival rates. As per the data from the American Cancer Society, by January 2023, approximately 20,380 cases and 11,310 deaths resulting from acute myeloid leukemia (AML) are expected amongst adults. Therefore, the increasing prevalence of myeloid leukemia is a contributor to the expansion of the myelodysplastic syndrome (MDS) drug market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13043&type=smp_x000D_

_x000D_

#Which Myelodysplastic Syndrome (MDS) Drugs Market Segments Are Growing the Fastest?#_x000D_

The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –_x000D_

_x000D_

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs_x000D_

2) By Route Of Administration: Oral, Parenteral_x000D_

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts_x000D_

4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers_x000D_

_x000D_

Subsegments:_x000D_

1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents_x000D_

2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide_x000D_

_x000D_

#Which Industry Trends Are Shaping the Future of the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_

Leading organizations in the myelodysplastic syndrome (MDS) drugs market are honing their focus on creating novel products, specifically targeted therapy, which aims to enhance patient outcomes, cater to unique customer requirements, and be compatible with the ecosystem. Targeted therapy in relation to myelodysplastic syndromes uses drugs designed expressly to target genetic abnormalities or molecular irregularities in cancer cells, promising improved results with its specific focus on abnormal cells, while limiting harm to healthy ones. For example, Tibsovo (ivosidenib) was approved by the U.S. Food and Drug Administration (FDA) in October 2023, for treating adults suffering from relapsed or refractory (R/R) myelodysplastic syndromes with an isocitrate dehydrogenase-1 (IDH1) mutation. To assess the effectiveness for this new usage, Tibsovo underwent testing in an open-label, single-arm, multicenter research including 18 adult patients who have relapsed or refractory MDS with an IDH1 mutation._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report_x000D_

_x000D_

#Which Countries Are Leading the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13043_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the myelodysplastic syndrome (mds) drugs market, and how is it changing globally?_x000D_

2. Who are the major companies in the myelodysplastic syndrome (mds) drugs market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the myelodysplastic syndrome (mds) drugs market right now?_x000D_

4. Which products or customer segments are growing the most in the myelodysplastic syndrome (mds) drugs market?_x000D_

5. What factors are helping or slowing down the growth of the myelodysplastic syndrome (mds) drugs market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the myelodysplastic syndrome (mds) drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Current and Projected Market Size of the Myelodysplastic Syndrome (MDS) Drugs Market Through 2034?

In recent times, the market size for myelodysplastic syndrome (MDS) drugs has shown robust growth. Projected growth indicates that it will rise from $3.47 billion in 2024 to $3.73 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.5%. This hike during the historical period is a result of factors such as the aging population, advances in targeted therapies, clinical trials, and heightened awareness.

In the upcoming years, the market size for drugs used to treat myelodysplastic syndrome (MDS) is projected to experience robust expansion, ballooning to $5.12 billion by 2029 with a compound annual growth rate (CAGR) of 8.2%. This promising growth projected in the forecast period can be credited to advances in genomic research, the development of immunotherapies, the global augmentation of healthcare, and the identification of biomarkers. Noteworthy trends for the forecast period comprise personalized medicine, the increasing use of combinatorial therapies, management of symptoms, and enhanced data sharing and collaboration.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

What Are the Core Market Drivers Propelling Growth in the Myelodysplastic Syndrome (MDS) Drugs Industry?

The upward trend in utilization of cancer treatment methods such as chemotherapy and radiation is projected to enhance the expansion of the myelodysplastic syndrome (MDS) drug market. Medications used in chemotherapy are designed to destroy cancerous cells, while radiation employs high-intensity radiation doses to exterminate cancer cells and decrease tumour rates. Unfortunately, these therapies have adverse effects on the stem cells in the bone marrow, which are responsible for generating new blood cells. This disruption in cell creation contributes to MDS occurrence. MDS drugs, however, present several advantages in the control and treatment of MDS, an array of disorders identified by irregular blood cell production in the bone marrow. A case in point is the analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based establishment, which anticipates a 16% surge in the radiotherapy treatment courses by 2025, based on projected cancer rates. Consequently, the growth of the myelodysplastic syndrome (MDS) drug market is being fueled by the increased reliance on cancer treatment methods such as chemotherapy and radiation.

Myelodysplastic Syndrome (MDS) Drugs Market Driver: Escalating Myeloid Leukemia Cases Spur Myelodysplastic Syndrome (MDS) Drug Treatment Market

 

How Is the Myelodysplastic Syndrome (MDS) Drugs Market Segmented?

The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs

2) By Route Of Administration: Oral, Parenteral

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts

4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents

2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13043&type=smp

Which Regions Are Driving the Next Phase of the Myelodysplastic Syndrome (MDS) Drugs Market Growth?

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Myelodysplastic Syndrome (MDS) Drugs Industry?

Major businesses in the myelodysplastic syndrome (MDS) drug market are focusing their efforts on developing innovative products such as targeted therapies to enhance patient outcomes, cater to specific client demands, and adapt to the ecosystem. Targeted therapy for MDS involves the use of drugs that explicitly target cancer cells with genetic mutations or molecular abnormalities, with the aim of selectively eliminating these abnormal cells while minimizing harm to healthy cells. For example, the U.S. FDA approved Tibsovo (ivosidenib) in October 2023 for treating adult patients with relapsed or refractory (R/R) MDS who have an isocitrate dehydrogenase-1 (IDH1) mutation. The efficacy of Tibsovo for this new usage was assessed in an open-label, single-arm, multicenter study that involved 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.

View the full report here:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

How Is the Myelodysplastic Syndrome (MDS) Drugs Market Defined and What Are Its Core Parameters?

Myelodysplastic syndrome (MDS) drugs are medications used to treat myelodysplastic syndrome, a collection of several bone marrow illnesses in which the bone marrow fails to create enough healthy blood cells. They work by helping to restore normal gene function in bone marrow cells and produce more red blood cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13043

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theMyelodysplastic Syndrome (MDS) Drugs Market?

The expanding usage of cancer treatments like chemotherapy and radiation is anticipated to propel the myelodysplastic syndrome (MDS) drug market. Chemotherapy, which uses medication to eliminate cancer cells, and radiation, which uses high doses of radiation to destroy cancer cells and diminish tumors, both affect the bone marrow’s stem cells responsible for creating new blood cells. This detrimental impact disrupts the normal rhythm of cell production and triggers MDS. MDS drugs provide numerous advantages in controlling and curing MDS, a collection of disorders marked by irregular blood cell production in the bone marrow. Based on the ESTRO-HERO (Health Economics in Radiation Oncology) evaluation by the European Society of Radiation Oncology, a Belgium-based institution, and taking into account the predicted cancer distributions in 2025, there could be a 16% surge in radiotherapy treatment plans. Thus, expanded cancer treatment exposure, like chemotherapy and radiation, fuels the myelodysplastic syndrome (MDS) drug market growth.

Myelodysplastic Syndrome (MDS) Drugs Market Driver: An Uptick in Myeloid Leukemia Cases Pushes the Myelodysplastic Syndrome (MDS) Drug Treatment Market

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

How Will the Growth Rate of theMyelodysplastic Syndrome (MDS) Drugs Market Impact Industry Trends by 2034?

The market size for drugs treating myelodysplastic syndrome (MDS) has witnessed a significant surge in recent times. It is projected to expand from $3.47 billion in 2024 to $3.73 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.5%. This upward trend during the historical timeline is due to factors such as the growing elderly population, progress in targeted therapies, numerous clinical trials, and heightened awareness.

The market for drugs treating myelodysplastic syndrome (MDS) is projected to experience vigorous expansion in the coming years. By 2029, it is anticipated to achieve a value of $5.12 billion by registering a compound annual growth rate (CAGR) of 8.2%. This growth during the projection period can be credited to developments such as genomic research, advancements in immunotherapies, the worldwide expansion of healthcare systems, and the identification of biomarkers. The forecast period is also expected to witness significant trends like personalized medication, combination therapies, management of symptoms, and active collaboration and data sharing.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13043

What Key Market Trends and Innovations Are Shaping the Future of theMyelodysplastic Syndrome (MDS) Drugs Industry?

Top businesses in the myelodysplastic syndrome (MDS) drug industry focus on rolling out innovations such as targeted treatments to improve patient health, cater to individual customer requirements and seamlessly integrate within the ecosystem. This targeted approach for MDS hones in on specific genetic aberrations or molecular anomalies in cancer cells using specialized drugs, with the intention of bettering patient outcomes by only targeting abnormal cells and reducing damage to healthy tissue. For example, in October 2023, Tibsovo (ivosidenib) received the approval of the U.S. Food and Drug Administration for treating adult patients with relapsed or refractory myelodysplastic syndromes that featured an isocitrate dehydrogenase-1 (IDH1) mutation. The efficacy of Tibsovo for this fresh application was assessed in a study conducted across numerous centers, in an open-label, single-arm fashion, involving 18 adult patients with recurrent or refractory MDS having an IDH1 mutation.

Which Companies Are Leading the Charge in Expanding theMyelodysplastic Syndrome (MDS) Drugs Market Growth?

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

How is the Global Myelodysplastic Syndrome (MDS) Drugs Market Segemented?

The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs

2) By Route Of Administration: Oral, Parenteral

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts

4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents

2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13043&type=smp

Which Geographics are Influencing the Growth of the Myelodysplastic Syndrome (MDS) Drugs Market?

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Myelodysplastic Syndrome (MDS) Drugs Market 2025, By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Respiratory Diseases Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Gastrointestinal Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the Myelodysplastic Syndrome (MDS) Drugs market grown in recent years?

The market size for drugs addressing myelodysplastic syndrome (MDS) has markedly expanded in the preceding years. It’s projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.5%. Factors such as an ageing population, advancements in targeted therapies, increased awareness, and clinical trials have contributed to its growth during the historical period.

How is the myelodysplastic syndrome (mds) drugs market size expected to evolve during the forecast period?

In the forthcoming years, the market for myelodysplastic syndrome (MDS) drugs is projected to witness robust growth. The market is predicted to attain a value of $5.12 billion by 2029, expanding at a compound annual growth rate (CAGR) of 8.2%. This enhancement during the forecast period can be ascribed to elements such as genomic research, immunotherapies, worldwide healthcare expansion and biomarker identification. Prominent trends expected in this period encompass personalized medicine, combinatorial therapies, symptom management, and data sharing and collaboration.

Get your myelodysplastic syndrome (mds) drugs market report here!

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Which key drivers are propelling the myelodysplastic syndrome (mds) drugs market’s growth?

The growth of the myelodysplastic syndrome (MDS) drug market is anticipated to rise due to growing exposure to cancer therapies such as chemotherapy and radiation. Chemotherapy, which involves medications to eliminate cancer cells, and radiation, a treatment that uses high radiation doses to destroy cancer cells and shrink tumors, both have damaging effects on the bone marrow’s stem cells. These cells are responsible for creating new blood cells and their disruption could lead to the development of MDS. MDS drugs, beneficial for managing and treating MDS, a group of disorders that result in abnormal production of blood cells in the bone marrow, are needed. As per an analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, it is projected that by 2025, there will be a 16% increase in radiotherapy treatment courses. Therefore, the myelodysplastic syndrome (MDS) drug market growth is being prompted by increasing exposure to cancer treatments like chemotherapy and radiation. In addition, the surge in cases of myeloid leukemia is expected to further stimulate the expansion of the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia, a cancer originating from the bone marrow affecting the cells that produce various blood cells, can be targeted directly by MDS drugs. These drugs work to improve bone marrow function, reduce the risk of complications from low blood cell counts, decrease reliance on chemotherapy and transplants, and increase survival rates for individuals with MDS. As indicated by the American Cancer Society, a US-based health organization, the number of acute myeloid leukemia (AML) cases is predicted to be approximately 20,380 with 11,310 fatalities in adults during 2023. Therefore, the rise in myeloid leukemia cases is a key growth driver for the myelodysplastic syndrome (MDS) drug market.

What are the market segments in the myelodysplastic syndrome (mds) drugs industry?

The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs

2) By Route Of Administration: Oral, Parenteral

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts

4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents

2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Which leading companies are shaping the growth of the myelodysplastic syndrome (mds) drugs market?

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

What key trends are currently impacting the myelodysplastic syndrome (mds) drugs market’s development?

Major firms in the myelodysplastic syndrome (MDS) drug market dedicate their efforts to the creation of novel products such as targeted therapies with the intention to boost patient health results, fulfill distinct customer requirements, and adapt to the environment. Targeted treatments for myelodysplastic syndromes (MDS) deploy specific drugs that identify and target genetic alterations or molecular irregularities in cancer cells with the purpose of enhancing results by selectively focusing on abnormal cells, aiming to reduce harm to normal tissues. For example, in October 2023, Tibsovo (ivosidenib) was authorized by the U.S. Food and Drug Administration (FDA) for the treatment of adults suffering from relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation. The effectiveness of using Tibsovo for this fresh use was assessed in a single-arm, open-label, multicenter study of 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

Which geographic areas are influencing the growth of the myelodysplastic syndrome (mds) drugs market?

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Respiratory Diseases Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Gastrointestinal Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Myelodysplastic Syndrome (MDS) Drugs Market’s Growth Rate Evolve Over the Forecast Period to 2034?

There has been considerable growth in the myelodysplastic syndrome (MDS) drugs market in the past few years. The market is projected to expand from $3.47 billion in 2024 to $3.73 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.5%. The significant growth during the historical period is due to factors such as an aging population, progress in targeted therapies, clinical trials, and heightened awareness.

The market for drugs treating myelodysplastic syndrome (MDS) is anticipated to experience significant expansion in the coming years, reaching an estimation of $5.12 billion in 2029, with a compound annual growth rate (CAGR) of 8.2%. This predicted growth in the market during the forecast period is linked to advancements in genomic research, immunotherapies, a global surge in healthcare infrastructure, and the identification of biomarkers. Key trends expected during this forecast period involve the focusing on personalized medicine, use of combinatorial therapies, effective symptom management, and an increase in data sharing and collaboration.

What External and Internal Drivers Are Contributing to the Growth of the Myelodysplastic Syndrome (MDS) Drugs Market’s Growth?

The growth of the myelodysplastic syndrome (MDS) drug market is anticipated to be fueled by increasing interactions with cancer therapies like chemotherapy and radiation. Chemotherapy implies the utilization of medication for eliminating cancer cells, while radiation denotes a cancer solution utilizing high amounts of radiation to destroy cancer cells and shrink tumors. Chemotherapy drugs and radiation therapy inflict harm on the bone marrow’s stem cells, which are the chief creators of new blood cells, disrupting natural cell creation and triggering MDS. These drugs designed for MDS, which is a cluster of disorders marked by abnormal blood cell production in the bone marrow, are instrumental in management and treatment. As per the ESTRO-HERO (Health Economics in Radiation Oncology) report, analyzed by the European Society of Radiation Oncology (ESTRO), a Belgium-based entity, cancer’s expected distribution in 2025 is anticipated to lead to a 16% rise in the radiotherapy treatment program. Therefore, increased interaction with cancer therapies such as chemotherapy and radiation fuels the growth of the MDS drug market.

Myelodysplastic Syndrome (MDS) Drugs Market Driver: Myeloid Leukemia Incidence Spike Pumping Up Myelodysplastic Syndrome (MDS) Drug Treatment Market

 

Get Your Free Sample of the Global Myelodysplastic Syndrome (MDS) Drugs Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Who Are the Influential Players Reshaping the Myelodysplastic Syndrome (MDS) Drugs Market Landscape?

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

What New and Evolving Trends Are Having a Lasting Impact on the Myelodysplastic Syndrome (MDS) Drugs Market?

Leading businesses in the myelodysplastic syndrome (MDS) drugs market concentrate on bringing forth novel products such as targeted therapies to enhance patient results, cater to specific customer requirements, and adapt to the ecosystem. Targeted treatments for MDS leverage drugs designed explicitly to target genetic mutations or molecular irregularities in cancer cells, with the objective to enhance results by selectively targeting abnormal cells and reducing harm to healthy tissues. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) granted approval for Tibsovo (ivosidenib) for treating adult patients afflicted with relapsed or refractory (R/R) MDS having an isocitrate dehydrogenase-1 (IDH1) mutation. The efficacy of Tibsovo for this fresh indication was analyzed in a transparent, single-arm, multi-center study involving 18 adult patients suffering from relapsed or refractory MDS having an IDH1 mutation.

Get Instant Access to the Global Myelodysplastic Syndrome (MDS) Drugs Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

What Major Market Segments Define the Scope and Growth of the Myelodysplastic Syndrome (MDS) Drugs Market?

The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs

2) By Route Of Administration: Oral, Parenteral

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts

4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents

2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

Which Geographic Locations Are Critical to the Growth of the Myelodysplastic Syndrome (MDS) Drugs Market?

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Key Characteristics That Define the Myelodysplastic Syndrome (MDS) Drugs Market?

Myelodysplastic syndrome (MDS) drugs are medications used to treat myelodysplastic syndrome, a collection of several bone marrow illnesses in which the bone marrow fails to create enough healthy blood cells. They work by helping to restore normal gene function in bone marrow cells and produce more red blood cells.

Browse Through More Similar Reports By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Respiratory Diseases Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Gastrointestinal Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: